BioXcel Therapeutics (BTAI) Competitors $1.82 -0.10 (-5.21%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.01 (-0.27%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. MURA, NAII, ENLV, PMN, RNXT, QTTB, GRCE, LSB, JATT, and RLYBShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Mural Oncology (MURA), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Q32 Bio (QTTB), Grace Therapeutics (GRCE), Lakeshore Biopharma (LSB), JATT Acquisition (JATT), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Mural Oncology Natural Alternatives International Enlivex Therapeutics ProMIS Neurosciences RenovoRx Q32 Bio Grace Therapeutics Lakeshore Biopharma JATT Acquisition Rallybio Mural Oncology (NASDAQ:MURA) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts prefer MURA or BTAI? Mural Oncology presently has a consensus price target of $13.00, indicating a potential upside of 328.90%. BioXcel Therapeutics has a consensus price target of $42.60, indicating a potential upside of 2,084.62%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk and volatility, MURA or BTAI? Mural Oncology has a beta of 5.28, indicating that its share price is 428% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Does the MarketBeat Community favor MURA or BTAI? BioXcel Therapeutics received 239 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 67.67% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformMural OncologyOutperform Votes880.00% Underperform Votes220.00% BioXcel TherapeuticsOutperform Votes24767.67% Underperform Votes11832.33% Which has better earnings and valuation, MURA or BTAI? BioXcel Therapeutics has higher revenue and earnings than Mural Oncology. Mural Oncology is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$207.45M-$7.58-0.40BioXcel Therapeutics$2.27M4.72-$179.05M-$25.97-0.08 Is MURA or BTAI more profitable? Mural Oncology has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -70.10% -61.30% BioXcel Therapeutics -3,119.33%N/A -105.04% Do insiders and institutionals have more ownership in MURA or BTAI? 80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 0.1% of Mural Oncology shares are owned by company insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor MURA or BTAI? In the previous week, Mural Oncology had 2 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for Mural Oncology and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Mural Oncology's score of 0.29 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mural Oncology Neutral BioXcel Therapeutics Very Positive SummaryBioXcel Therapeutics beats Mural Oncology on 10 of the 17 factors compared between the two stocks. Remove Ads Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.73M$6.37B$5.35B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-0.066.8421.7517.84Price / Sales4.72225.35378.4594.09Price / CashN/A65.6738.1534.64Price / Book-0.065.866.404.01Net Income-$179.05M$141.86M$3.20B$247.31M7 Day Performance32.65%9.54%6.79%6.75%1 Month Performance-8.45%-12.21%-8.41%-6.62%1 Year Performance-95.57%-11.90%10.21%0.00% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics3.9979 of 5 stars$1.82-5.2%$42.60+2,240.7%-95.9%$9.99M$2.27M-0.0590Positive NewsMURAMural Oncology2.6155 of 5 stars$1.16+2.7%$13.00+1,020.7%-75.6%$19.98MN/A-0.13119Options VolumeNews CoverageGap UpNAIINatural Alternatives International1.5002 of 5 stars$3.12-5.7%N/A-54.6%$19.34M$121.85M-2.42290Short Interest ↓Gap UpENLVEnlivex Therapeutics3.3005 of 5 stars$0.89+0.2%$10.00+1,023.6%-43.9%$19.05MN/A-0.9170Short Interest ↓Positive NewsGap UpPMNProMIS Neurosciences3.1292 of 5 stars$0.58-5.1%$6.00+929.7%-75.5%$19.05MN/A-5.835Positive NewsRNXTRenovoRx2.0115 of 5 stars$0.79-10.4%$6.00+659.5%-30.8%$18.96M$43,000.00-1.396Short Interest ↑Gap UpHigh Trading VolumeQTTBQ32 Bio2.4066 of 5 stars$1.53-6.7%$24.71+1,515.3%-93.4%$18.66M$-6,651,000.00-0.1139Positive NewsGRCEGrace Therapeutics2.1016 of 5 stars$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap DownLSBLakeshore Biopharma0.6825 of 5 stars$1.95-6.7%N/AN/A$18.15M$672.27M0.00773Upcoming EarningsShort Interest ↑High Trading VolumeJATTJATT AcquisitionN/A$1.03-5.1%N/A-64.0%$17.77MN/A0.003High Trading VolumeRLYBRallybio2.3964 of 5 stars$0.42-5.6%$9.75+2,194.7%-87.7%$17.68M$636,000.00-0.2740Analyst DowngradeNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies Mural Oncology Alternatives Natural Alternatives International Alternatives Enlivex Therapeutics Alternatives ProMIS Neurosciences Alternatives RenovoRx Alternatives Q32 Bio Alternatives Grace Therapeutics Alternatives Lakeshore Biopharma Alternatives JATT Acquisition Alternatives Rallybio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTAI Stock Free BTAI Stock Alerts